Programmed Death Receptor-1 Blocking Antibody class drugs

3 results

  • loqtorzi

    (toripalimab-tpzi)
    Coherus BioSciences, Inc.
    LOQTORZI is indicated for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine. It is also indicated as a single agent for adults with recurrent unresectable or metastatic NPC progressing after platinum chemotherapy.
    Medication Details
    Drug Interactions

  • tecentriq hybreza

    (atezolizumab and hyaluronidase-tqjs)
    Genentech, Inc.
    TECENTRIQ HYBREZA is indicated for treating various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults.
    Medication Details
    Drug Interactions